Target Price | $1,179.36 |
Price | $1,138.81 |
Potential | 3.56% |
Number of Estimates | 22 |
22 Analysts have issued a price target Regeneron Pharmaceuticals 2025 . The average Regeneron Pharmaceuticals target price is $1,179.36. This is 3.56% higher than the current stock price. The highest price target is $1,300.00 14.15% , the lowest is $805.00 29.31% . | |
A rating was issued by 28 analysts: 20 Analysts recommend Regeneron Pharmaceuticals to buy, 6 to hold and 2 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Regeneron Pharmaceuticals stock has an average upside potential 2025 of 3.56% . Most analysts recommend the Regeneron Pharmaceuticals stock at Purchase. |
22 Analysts have issued a sales forecast Regeneron Pharmaceuticals 2024 . The average Regeneron Pharmaceuticals sales estimate is $14.2b . This is 5.01% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $14.6b 7.90% , the lowest is $13.5b 0.18% .
This results in the following potential growth metrics:
2023 | $13.1b | 7.76% |
---|---|---|
2024 | $14.2b | 7.99% |
2025 | $15.4b | 8.55% |
2026 | $16.5b | 7.13% |
2027 | $18.1b | 9.76% |
2028 | $18.6b | 2.79% |
9 Analysts have issued an Regeneron Pharmaceuticals EBITDA forecast 2024. The average Regeneron Pharmaceuticals EBITDA estimate is $5.7b . This is 25.14% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $6.5b 41.44% , the lowest is $5.2b 13.69% .
This results in the following potential growth metrics and future EBITDA Margins:
2023 | $4.8b | 13.76% |
---|---|---|
2024 | $5.7b | 19.82% |
2025 | $6.3b | 9.63% |
2026 | $7.1b | 12.70% |
2027 | $8.0b | 12.76% |
2028 | $10.3b | 29.75% |
2023 | 36.36% | 19.97% |
---|---|---|
2024 | 40.35% | 10.97% |
2025 | 40.75% | 0.99% |
2026 | 42.87% | 5.20% |
2027 | 44.04% | 2.73% |
2028 | 55.59% | 26.23% |
13 Regeneron Pharmaceuticals Analysts have issued a net profit forecast 2024. The average Regeneron Pharmaceuticals net profit estimate is $4.2b . This is 0.16% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $4.8b 16.53% , the lowest is $3.6b 14.43% .
This results in the following potential growth metrics and future Net Margins:
2023 | $3.8b | 9.03% |
---|---|---|
2024 | $4.2b | 8.77% |
2025 | $4.4b | 6.51% |
2026 | $5.0b | 11.79% |
2027 | $5.8b | 16.99% |
2028 | $6.4b | 11.07% |
2023 | 29.21% | 15.58% |
---|---|---|
2024 | 29.42% | 0.72% |
2025 | 28.87% | 1.87% |
2026 | 30.12% | 4.33% |
2027 | 32.11% | 6.61% |
2028 | 34.69% | 8.03% |
13 Analysts have issued a Regeneron Pharmaceuticals forecast for earnings per share. The average Regeneron Pharmaceuticals <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is $37.82 . This is 0.16% higher than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is $44.00 16.53% , the lowest is $32.31 14.43% .
This results in the following potential growth metrics and future valuations:
2023 | $34.77 | 9.03% |
---|---|---|
2024 | $37.82 | 8.77% |
2025 | $40.28 | 6.50% |
2026 | $45.03 | 11.79% |
2027 | $52.68 | 16.99% |
2028 | $58.51 | 11.07% |
Current | 30.16 | 47.19% |
---|---|---|
2024 | 30.32 | 0.16% |
2025 | 28.47 | 6.10% |
2026 | 25.47 | 10.54% |
2027 | 21.77 | 14.53% |
2028 | 19.60 | 9.97% |
Based on analysts' sales estimates for 2024, the Regeneron Pharmaceuticals stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 8.42 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 8.92 .
This results in the following potential growth metrics and future valuations:
Current | 8.78 | 33.84% |
---|---|---|
2024 | 8.42 | 4.75% |
2025 | 7.76 | 7.88% |
2026 | 7.24 | 6.65% |
2027 | 6.60 | 8.89% |
2028 | 6.42 | 2.71% |
Current | 9.31 | 31.90% |
---|---|---|
2024 | 8.92 | 4.77% |
2025 | 8.22 | 7.88% |
2026 | 7.67 | 6.65% |
2027 | 6.99 | 8.89% |
2028 | 6.80 | 2.71% |
Regeneron Pharmaceuticals...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.